The utility of bone marrow transplantation for childhood leukemia in patients unable to achieve a remission prior to transplant is controversial. To address this issue, we analyzed a subset of patients with advanced leukemia entered on prospective transplant trials at our hospital. Fifty-eight patients with ALL or AML (age 1-19) were identified. They had failed standard chemotherapy and were in relapse (22 in 1st, 27 in 2nd, three in 3rd, and three in 4th) or had never achieved an initial remission (three) at the time of transplant. Fifty-two patients received marrow from mismatched family members (haplo or DR-identical), while six received marrow from matched siblings. Most patients received myeloablative therapy consisting of total body irradiation, etoposide, cyclophosphamide, and cytosine arabinoside. Marrow from mismatched donors was T cell depleted. Only one of 52 patients transplanted with a mismatched donor survived long-term while three of six patients transplanted in relapse with a fully matched sibling donor are alive 6-10 years post BMT. The major causes of death were infection (39%) and relapse (28%). Acute GVHD grade III-IV was noted in 7% of patients. A comparable group of patients with leukemia transplanted at our center in remission using similarly mismatched family member donors (haplo or DR-identical) had an event-free survival of 28%. In conclusion, our data suggest that BMT utilizing mismatched family member donors is a poor option for patients in relapse at the time of transplant. New treatment strategies need to be developed to effectively manage these patients. Bone Marrow Transplantation (2000) 25, 943-948. Keywords: relapsed leukemia; BMT; mismatched donors Bone marrow transplantation (BMT) is increasingly utilized as an aggressive therapeutic option in children with relapsed or high-risk leukemia, although there is significant
controversy as to which patients will benefit the most from this treatment. In acute lymphoblastic leukemia (ALL), BMT has been employed for patients in first remission with poor prognostic characteristics (age Ͻ1 year, poor response to induction chemotherapy or specific chromosomal translocations). [1] [2] [3] [4] BMT is also considered for patients in second remissions who have relapsed within 18-24 months following initial diagnosis. 2, 5, 6 Similarly, BMT is recommended as front-line therapy for patients with AML if they have a matched sibling donor or if they relapse with their disease. 7 Unfortunately, 20-40% of children with acute leukemia will relapse once or multiple times and some of them will fail re-induction therapy and be unable to achieve a subsequent remission. Patients with active acute leukemia at the time of intended transplant are at extremely high risk of treatment failure and the utility of BMT in these cases is controversial.
Previously, our program had concentrated on transplants using mismatched donors. A cohort of high-risk patients that still had active leukemia present prior to undergoing myeloablative therapy was accepted for transplant. Acceptance of these patients was partially based upon the fact that use of mismatched or matched family member donors resulted in minimal delays in initiating transplant therapy, and survival with conventional chemotherapy was improbable. In fact, a preliminary report from our center suggested that patients with refractory ALL at time of transplant could be cured with this approach. 8 Additionally, BMT using partially matched family member donors for pediatric patients with leukemia in remission had yielded encouraging results. 9, 10 In this report, we have updated the data on subjects receiving transplants from mismatched or matched family member donors to treat relapsed/refractory acute leukemia. Results from this analysis now suggest that transplanting leukemia patients in relapse is a poor option, although it may be considered for patients with unfavorable disease status when a matched sibling donor is available.
Materials and methods

Study population and definition of high-risk patients
Between March 1987 and September 1994, 58 high-risk patients (ages 1-19) with leukemia underwent bone marrow transplantation using a family member donor (Table 1 ). All high-risk patients had failed standard chemotherapy, and were either in 'relapse' (22 in 1st, 27 in 2nd, three in 3rd), defined as more than 5% blasts in the marrow at the time of transplant, or had 'primary refractory disease' (three), characterized by failing to achieve an initial remission prior to transplant. Acute lymphoblastic leukemia (ALL) was the underlying disease in 42 patients and acute nonlymphoblastic leukemia (ANLL) in 16 patients. During the same time period, 79 patients with acute leukemia in remission at time of transplant underwent BMT using a mismatched family member donor. All patients and/or their guardians signed informed consent approved by the committee on the use of human subjects and research at the University of Iowa.
Donor type
For the 58 high-risk patients, six received marrow from a genotypically matched sibling donor, while 52 received marrow from mismatched family member donors. Of the 52 mismatched marrows, 11 were DR-identical (four were 5/6 matched, seven were 4/6 matched). 28 were haploidentical (3/6), and 13 were 4/6 matched but DR-mismatched. HLA testing was performed by serological methods and DR-identity was not confirmed by DNA typing. The availability of a DR-identical family member took precedence over a haploidentical family member in our donor selection algorithm. 
Supportive care
Patients were hospitalized in single rooms with high efficiency particulate Hepa filtration air (HEPA) systems. Patients received trimethoprim-sulfamethoxazole for pneumocystis prophylaxis, i.v. acyclovir for herpes virus prophylaxis, and after 1989 twice weekly i.v. amphotericin and daily intranasal amphotericin for anti-fungal prophylaxis. Anti-bacterial prophylaxis consisted of weekly IVIG and broad-spectrum antibiotics for a white blood cell count Ͻ1000/l and/or temperature у38.5°C. Patients sero-negative for cytomegalovirus (CMV) with CMV sero-negative marrow donors received blood products from sero-negative donors and/or leuko-depleted blood products.
Marrow preparation
Bone marrow was obtained from donors under regional or general anesthesia. Mismatched donor marrow was depleted of T lymphocytes by the addition of CT-2 (a mouse IgM anti-human CD-2 antibody) and rabbit serum as a source of complement. 11 The marrow was given intravenously upon completion of the depletion process; the nucleated cell doses administered are summarized in Table  2 . Estimates of residual T cells were made as previously Number of nucleated marrow cells infused per kg recipient body weight. b Defined as achieving an ANC Ͼ500 for 3 consecutive days, unevaluable patients are those dying prior to day 28 post BMT with an ANC Ͻ500.
described. 12 Nearly all T cell depletions resulted in a two log loss of T cells from the graft.
Graft-versus-host disease
Graft-versus-host disease (GVHD) prophylaxis for patients receiving marrow from mismatched donors consisted of T lymphocyte depletion of the marrow as described above, as well as anti-lymphocyte or anti-thymocyte globulin (20 mg/kg i.v. every other day ϫ8 doses starting day Ϫ1) and methylprednisolone (1 mg/kg/day alternating with 2 mg/kg/day). Slow weaning of prednisone generally did not begin until 1-2 months post transplant. Patients with matched sibling donors received unmanipulated T cell nondepleted grafts, but were treated with anti-lymphocyte or anti-thymocyte globulin and prednisone similar to those patients with mismatched donors.
Evaluation of engraftment and relapse
Engraftment was defined as the time to neutrophil recovery, calculated from the time of transplant until the absolute neutrophil count (ANC) reached 500/l for 3 consecutive days. Bone marrow examinations with cytogenetics were also done routinely on days 14 and 28 to assess engraftment and donor chimerism, or at later times to confirm relapse.
Post-transplant statistical methods
Event-free survival (EFS) was estimated using the KaplanMeier method. 13 Since the sample size in one of the groups was quite small (n = 6), Fisher's exact test (two-tailed) was used to compare death rates at year 5 of follow-up. This time point was chosen since all patients were followed for at least 5 years.
Results
Engraftment
Full engraftment was achieved in all of the patients (6/6) receiving matched transplants, and in 37/52 patients receiving mismatched grafts. Five mismatched patients failed to engraft as documented by hypoplastic marrows and absolute neutrophil counts Ͻ500 on or after day 28. Two of the patients went on to receive second transplants, and all five died 28-98 days post BMT of an infectious complication. Nine other patients died prior to day 28 and thus were not evaluable for engraftment. Of those patients engrafting, the median time to an ANC Ͼ500 was 16.5 days (range 14-24 days) in those receiving matched marrow and 17 days (range 11-40 days) in those receiving mismatched marrow (Table 2) . had grade II acute GVHD and 21% (11/52) had grade I acute GVHD. Similarly, 50% (3/6) of patients receiving matched sibling donor transplants (T cell non-depleted) failed to develop acute GVHD (Figure 1 ). However, our incidence of acute GVHD may be under-estimated in the patients receiving mismatched grafts as 34 of the 52 patients in this study died before day 100.
Survival
Only 2% of patients (1/52) transplanted in relapse with mismatched marrow survived long term. The lone surviving patient from this group received marrow from a haploidentical parent (Figure 2 ). None of the 11 patients in this group transplanted with DR-identical donors are currently alive. In contrast, three of six patients (50%) transplanted in relapse with matched sibling donors are alive 7-11 years post BMT (P = 0.006). Outcome was not significantly different with regard to the original type of leukemia, with 4/42 patients (10%) transplanted for ALL and 0/16 patients (0%) transplanted for ANLL surviving long term (P = 0.57). Of the four long-term survivors, two developed grade Mismatched (n = 52) Overall (n = 58) P = 0.006 Figure 2 Actuarial probability of disease-free survival in patients transplanted in relapse using either a matched or mismatched family member donor. Also indicated is overall disease-free survival for all patients transplanted in relapse. Difference in survival between relapsed patients transplanted with matched vs mismatched donors was statistically significant (P = 0.006).
I GVHD, one developed grade II GVHD and one developed grade III GVHD. During the same time period that relapsed patients were undergoing transplant, 79 other patients with ALL or AML in remission were transplanted at our center with partially matched family member donors. These 'remission' patients had a 5-year EFS of 28% (Figure 3) . The difference in survival is statistically significant (P = 0.0003) when comparing patients transplanted in remission vs those transplanted in relapse.
Relapse
Combining patients with mismatched (52) and matched donors (six), disease recurrence was the primary cause of death in 26% of patients (15/58), with 21% of patients (9/42) with ALL and 38% of patients (6/16) with ANLL relapsing post transplant. Only one of six patients receiving marrow from a matched donor relapsed. The median time to relapse was 54 days (13-140) post BMT, and most patients died within 1 month following this diagnosis ( Table 2) . Three patients had refractory disease following the myeloablative therapy as documented by failure of blasts to clear from the bone marrow or blood at 2 weeks post BMT. None of the 15 patients that relapsed developed grade II-IV acute GVHD.
Adverse events
Non-relapse mortality was noted in 71% of patients (37/52) receiving mismatched marrow in relapse. Of the six patients receiving matched marrow, non-relapse causes of death were pneumonitis (1/6) and CMV pneumonia (1/6). As noted in Table 3 , the most common cause of death for all patients transplanted in relapse was infection (21/58). Fungal disease was listed as the primary cause of death for 13/58 patients. Three other patients with a different primary cause of death also had concurrent fungal infections. Aspergillus accounted for 10 of the 13 fungal deaths. There were four deaths due to viral infection (two adenovirus, one respiratory syncytial virus, and one cytomegalovirus). Four patients died of Epstein-Barr virus-lymphoproliferative dis- order (EBV-LPD). Respiratory failure/interstitial pneumonitis without documented infection accounted for four deaths. There were three cardiac deaths, two of which were directly related to the pre-transplant myeloablative therapy. There were three deaths attributed to renal failure. Two of these three patients had hemolytic uremic syndrome. There were two hemorrhagic deaths, both in the CNS, one of which was due to an arteriovenous malformation. Two deaths were attributed to veno-occlusive disease (VOD).
Discussion
Allogeneic bone marrow transplantation has played an important role in the treatment of recurrent or high-risk leukemia. However, the utility of bone marrow transplant for extremely high-risk patients such as those with primary refractory/resistant disease, those with multiple (Ͼ3) relapses or those with unresponsive relapsed disease at the time of transplant is controversial. Nonetheless, many of these patients are referred for BMT because of their universally poor outcome with a conventional chemotherapeutic approach. In 1990, a preliminary report from our group found a survival rate of 25% for 23 patients with ALL transplanted in relapse or with refractory disease using matched (four) and mismatched donors (19) . 8 However, a number of deaths occurred in the patients receiving mismatched transplants shortly after this report, although four of these original patients are currently alive. In our current analyses, we have included an additional 32 patients and have expanded our series to include those with ANLL and ALL. Of the 52 patients in this series transplanted in relapse with partially matched family member donors, only one is currently alive, while three of six patients with matched sibling donors and active disease at the time of transplant survive long-term.
Fleming et al 9 reported their BMT experience with partially matched family member donors for the treatment of relapsed ALL, including some patients with active disease at the time of transplant. Of the 23 patients transplanted in relapse, only four (17%) survived long term. Similar to our experience, patients transplanted in remission had a significant improvement in EFS compared to those transplanted in relapse. A number of other groups have reported their experiences transplanting very high-risk leukemia patients with matched unrelated donors. Balduzzi et al, 14 from Seattle, found a 10% disease-free survival rate and a 60% relapse rate for 28 pediatric ALL patients transplanted in relapse or third remission. In assessing other high-risk patients, including those with AML, CML, and lymphoma patients, no difference in survival was observed whether patients were transplanted with a matched sibling donor or a matched unrelated donor. Casper et al 15 noted a similarly poor outcome in children receiving unrelated donor marrow for treatment of advanced leukemia. Thirteen ALL patients were transplanted in greater than second CR or relapse and only two (15%) survived long term.
In contrast to these studies, Davies et al 16 recently reported on their unrelated donor experience. For ALL beyond CR2 or in relapse (n = 16), 2 year disease-free survival was 42% although, surprisingly, patients in first or second CR only had a 21% disease-free survival. It is possible that the improved survival noted in Davies' high-risk patient group was related to the higher incidence of GVHD and potentially concomitant graft-versus-leukemia (GVL) effect. In fact, in their study, 49% of patients receiving fully matched unrelated donor transplants and 67% of patients receiving mismatched unrelated donor transplants developed grade II-IV GVHD. However, an increased incidence of acute GVHD does not always translate into improved survival. Balduzzi in his series from Seattle reported an 83-98% incidence of grade II-IV acute GVHD for patients transplanted with matched or mismatched unrelated donors, respectively. Despite this incidence of GVHD, only 10% of high-risk ALL patients survived long term, and 60% of high-risk patients relapsed. In our study, the use of partially matched/haploidentical family member donors did not result in an exceptionally high incidence of acute GVHD, with only 23% developing grade II-IV GVHD, and none developing grade IV GVHD. Interestingly, all four survivors in our analysis (three matched and one haploidentical) had some degree of GVHD (two grade I, one grade II, one grade III). Despite the limited extent of GVHD in our patients, relapse was noted in only 26%. Not surprisingly, relapses occurred very early following transplant (median of 54 days). These relapses post BMT may reflect either the primary biology of the leukemia, a lack of a GVL effect, inadequate preparative therapy, or some combination of the above.
Bone marrow transplantation using partially matched donors and T cell-depleted grafts has previously been associated with an increased incidence of graft failure/rejection. 17, 18 However, this problem was not observed in our patient population. Discounting the 10 patients who died in the peri-transplant period from an infection, toxicity from chemotherapy, or resistant leukemia, engraftment was established in 44/49 patients (90%). While T cell depletion is critical in the haploidentical setting to limit acute GVHD, it is often at the expense of other toxicities, in particular an increased incidence of severe life-threatening infections. 19 Unfortunately, this was observed in our series where infection was the primary cause of death in 21 patients, accounting for 54% of nonrelapse mortality. Nearly one-half (10/21) of these infections were due to aspergillus and all occurred in patients Bone Marrow Transplantation receiving mismatched grafts. The risk of aspergillus infection may be increased due to the geographical location of our center, and in fact was the impetus to a recent study assessing the use of prophylactic intranasal amphotericin. 20 In addition, our patient population was heavily pretreated with multiple chemotherapeutic regimens, and it is likely that many were transplanted whilst having occult fungal disease that became manifest post transplant.
It is possible that an increased tempo of reducing immunosuppression or an alternative GVHD prophylaxis regimen would have been beneficial, potentially augmenting immunological recovery as well as a GVL effect. Our group and others who employ T cell depletion have begun to investigate the use of 'prophylactic' donor lymphocyte infusions in the post-BMT setting. 21, 22 Lee et al 23 recently reported on their experience with prophylactic reinfusion of a graded number of T cells for T cell-depleted allogeneic bone marrow grafts in adult patients with leukemias or lymphomas. These infusions were well tolerated and associated with an increased incidence of acute and chronic GVHD. Of note, a clear advantage in disease-free survival was seen in patients that developed chronic GVHD and grades II-IV acute GVHD. Further exploration of novel strategies to enhance GVL without inducing excessive GVHD and to control infectious complications may improve outcomes for BMT in advanced leukemia. In summary, partially matched family member bone marrow transplantation offers a greater number of patients the potential for transplant. This donor type is attractive due to the time constraints imposed by high-risk leukemias with respect to time needed to procure an unrelated donor. However, due to the high incidence of infectious complications and relapse, our current study suggests that BMT using mismatched grafts for patients with refractory or relapsed leukemia not in remission at the time of transplant is unlikely to be successful. Nonetheless, BMT might be considered for this high-risk patient population if a matched sibling donor is available.
